Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study

Figures

• 

  Fig. 1. Comparison of treatment effects on the first VTE recurrence, first any bleeding, first major bleed, and death events in high- and low-risk patient subgroups. *Not estimable. aCox proportional model with treatment as covariate. bIntention-to-treat patients. cAs-treated patients. Statistically significant p values (p < 0.05) are shown in bold text. CI confidence interval, VKA vitamin K antagonist, VTE venous thromboembolism, High-risk metastatic disease and/or antineoplastic treatment, low-risk no metastatic disease and no neoplastic treatment

• 

  Fig. 2. Kaplan–Meier estimates of the time to first VTE and bleeding events in high-risk patients. a Time to first VTE reccurence at 6 monthsab Time to first any bleeding event at 6 monthsbc Time to first major bleeding event at 6 monthsb. Significance set at 5% and p-value calculated using log-rank test. aITT population. bAST population. AST as-treated, ITT intention-to treat, VKA vitamin K antagonist, VTE venous thromboembolism

• 

  Fig. 3. Time to first event data following adjustment for potential prognostic factorsa assessed at study entry. aPrognostic variables applied to CLOT study. With the exception of treatment effect, only factors significant in a univariate analysis at the 0.10 significance level were considered in the process of building the final multivariate model. bIntention-to-treat population. cAs-treated population. dCrCl values were calculated using the Cockcroft-Gault formula. Normal: CrCl ≥ 60 mL/min; moderate impairment: 30 ≤ CrCl < 60 mL/min; severe impairment: CrCl < 30 mL/min. High-risk metastatic disease and/or antineoplastic treatment. Statistically significant p values (p < 0.05) are shown in bold text. CI confidence interval, CrCl creatinine clearance, ECOG PS Eastern Cooperative Oncology Group performance status, GI gastrointestinal, GU genitourinary, VKA vitamin K antagonist, VTE venous thromboembolism